Analysis of over 30,000 tumors found that co-mutation of CREBBP/EP300 and POLE/POLD1 strongly predicted elevated tumor mutational burden in microsatellite-stable disease (median 155.9 vs. 5.4 Mut/Mb) and was associated with improved survival and immunotherapy response. (Int J Mol Sci)
Co-mutations in CREBBP/EP300 and POLE/POLD1 identify high tumor mutational burden in MSS colorectal cancer
The CRC Digest